Related Experiment Video
Updated: Feb 14, 2026

Use of LysoTracker to Detect Programmed Cell Death in Embryos and Differentiating Embryonic Stem Cells
Published on: October 11, 2012
Dual function of programmed cell death 10 (PDCD10) in drug resistance
Cagri Urfali-Mamatoglu1, Hasan Hüseyin Kazan1, Ufuk Gündüz1
1Department of Biological Sciences, Middle East Technical University, Ankara, Turkey.
Abstract:
Drug resistance, a major challenge in cancer chemotherapy, is a result of several mechanistic alterations including resistance to apoptosis. Apoptosis is a well-controlled cell death mechanism which is regulated by several signaling pathways. Alterations in structure, function, and expression pattern of the proteins involved in the regulation of apoptosis have been linked to drug resistance. Programmed Cell Death 10 (PDCD10) protein is recently associated with the regulation of cell survival and apoptosis. However, the role of PDCD10 in drug resistance has not been clearly established. Here, we aimed to figure out the role of PDCD10 in resistance to anti-cancer agents in different cell lines. We found that PDCD10 expression was cell- and anti-cancer agent-specific; down-regulated in doxorubicin- and docetaxel-resistant MCF7 cells while up-regulated in doxorubicin-resistant HeLa cells. Down-regulation of PDCD10 expression by siRNA in parental MCF7 cells increased the resistance while it increased sensitivity in doxorubicin-resistant HeLa cells. Similarly, over-expression of PDCD10 in parental HeLa cells increased the resistance to doxorubicin while it re-sensitized doxorubicin-resistant MCF7 cells. Moreover, the alterations in PDCD10 expression led to changes in caspase 3/7 activity and the levels of apoptosis-related genes. Our results point out a possible dual role of PDCD10 in drug resistance for the first time in the literature and emphasize PDCD10 as a novel target for reversal of drug resistance in cancer.
Insights
Programmed Cell Death 10 (PDCD10) plays a dual role in cancer drug resistance. Modulating PDCD10 levels can either increase or decrease resistance, offering a novel target for overcoming chemotherapy challenges.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Drug resistance is a significant hurdle in cancer chemotherapy, often involving altered apoptosis pathways.
- Programmed Cell Death 10 (PDCD10) is implicated in cell survival and apoptosis, but its specific role in drug resistance remains unclear.
Purpose of the Study:
- To investigate the role of PDCD10 in mediating resistance to anti-cancer agents across various cell lines.
- To explore PDCD10 as a potential therapeutic target for reversing drug resistance in cancer.
Main Methods:
- Analysis of PDCD10 expression in drug-resistant versus parental cancer cell lines (MCF7, HeLa).
- Manipulation of PDCD10 levels using siRNA (down-regulation) and overexpression.
- Assessment of apoptosis markers, including caspase 3/7 activity and related gene expression.
Main Results:
- PDCD10 expression is cell- and drug-specific, showing down-regulation in doxorubicin/docetaxel-resistant MCF7 cells and up-regulation in doxorubicin-resistant HeLa cells.
- Altering PDCD10 levels demonstrated a dual effect: down-regulation increased resistance in MCF7 cells, while it enhanced sensitivity in resistant HeLa cells. Overexpression showed converse effects.
- Changes in PDCD10 expression correlated with altered caspase 3/7 activity and apoptosis-related gene expression.
Conclusions:
- PDCD10 exhibits a novel dual role in cancer drug resistance, influencing sensitivity and resistance depending on the cellular context and drug.
- Targeting PDCD10 presents a promising strategy for developing new therapies to overcome drug resistance in cancer treatment.
Related Concept Videos
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Rate-Programmed I
Resistivity
Resistance

